{"id":441223,"date":"2022-12-13T10:15:59","date_gmt":"2022-12-13T15:15:59","guid":{"rendered":"https:\/\/www.billingparadise.com\/blog\/?p=441223"},"modified":"2026-03-11T03:02:20","modified_gmt":"2026-03-11T08:02:20","slug":"new-covid-19-booster-vaccine-cpt-codes","status":"publish","type":"post","link":"https:\/\/www.billingparadise.com\/blog\/new-covid-19-booster-vaccine-cpt-codes\/","title":{"rendered":"New COVID-19 Booster Vaccine CPT codes"},"content":{"rendered":"

<\/h2>\n

New CPT codes for COVID-19 Booster Vaccine<\/h2>\n


\nCOVID-19 and its adaptation are still a threat to many individuals in the United States. The CDC has prioritized that people with symptoms even after receiving the covid vaccines that work in public domains, healthcare, and other high-population settings must use these covid booster vaccines for safety measures for themselves their loved ones, and the people surrounding them.<\/span><\/p>\n

It is not because of the raising <\/span>covid-19 conditions<\/span><\/a>, but because of safety concerns to stop the adaptation of a new strain of the covid-19 virus. So many healthcare organizations such as The CDC, WHO, AMA, and FDA have approved booster vaccine doses from a few of the best biotech companies.<\/span><\/p>\n

The <\/span>AMA (American Medical Association)<\/span><\/a> has declared newly added and updated to its Current Procedural nomenclature (CPT) code set to incorporate eight new codes for the bivalent COVID-19 vaccine doses from Moderna and Pfizer-BioNTech.<\/span><\/p>\n

The US Food and Drug Administration (FDA) amended the emergency use authorizations for each Moderna\u2019s and Pfizer-BioNTech\u2019s vaccines to authorize bivalent formulations to run as one booster shot a minimum of 2 months following primary or booster vaccination. The bivalent vaccines contain 2 RNA components: one for the initial COVID-19 strain and therefore the alternative for the additional common BA.4 and BA.5 subvariants of the now-dominant letter of the alphabet strain.<\/span><\/p>\n

The same day because of the FDA\u2019s announcement, AMA discharged the new CPT codes for the bivalent COVID-19 booster doses therefore suppliers will document and bill for administering boosters as presently because the vaccinum doses will be on the market this fall.<\/span><\/p>\n

Across the state, 108 million Americans or over half those eligible to be boosted\u2014have nevertheless to receive their initial booster shot despite proof that they’re safe and extremely effective against severe sickness outcomes.<\/span><\/p>\n

The consultatory Committee on immunization Practices should currently review and approve the employment of the bivalent COVID-19 vaccinum doses. The Committee is regularly to satisfy nowadays. Previous approvals for original COVID-19 vaccines stirred fairly quickly, taking simply one or two weeks.<\/span><\/p>\n

The AMA (American Medical Association) appearance forward to the review of the redesigned COVID-19 boosters by the consultatory Committee on Immunization Practices and its unfinished recommendations on clinical uses for every product. As we have a tendency to inure potential fall and winter surges of COVID-19, the AMA encourages all citizens will be eligible to induce a booster and review the on-the-market choices with a doctor.<\/span><\/p>\n

The new CPT codes embrace 91312, 91313, 0124A, and 0134A, which will be effective to be used forthwith following the FDA\u2019s change of the emergency use authorization for Moderna\u2019s new COVID-19 booster in folks that must be eighteen years or older and Pfizer-BioNTech\u2019s new COVID-19 booster in people must be twelve years or older.<\/span><\/p>\n

The other four new CPT codes\u2014 91314, 91315, 0144A, and 0154A\u2014will be effectively to be used once Food and Drug Administration authorizes Moderna\u2019s new COVID-19 booster for youngsters between the ages of six and eleven years and Pfizer-BioNTech\u2019s new COVID-19 booster for youngsters between five and eleven years.<\/span><\/p>\n

Moderna bivalent boosters for children codes and descriptions:<\/b><\/h3>\n

91314 – <\/b>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative-free, 25 mcg\/0.25 mL dosage, for intramuscular use<\/span><\/p>\n

0144A –\u00a0 <\/b>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRN-LNP, spike protein, bivalent, preservative-free, 25 mcg\/0.25 mL dosage, a booster dose<\/span><\/p>\n

Moderna bivalent boosters for adults codes and descriptions:<\/b><\/h3>\n

91313 – <\/b>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative-free, 50 mcg\/0.5 mL dosage, for intramuscular use<\/span><\/p>\n

0134A –\u00a0 <\/b>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative-free, 50 mcg\/0.5 mL dosage, a booster dose<\/span><\/p>\n

Pfizer-BioNTech\u2019s bivalent COVID-19 boosters for children codes and descriptions:<\/b><\/h3>\n

91315 – <\/b>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative-free, 10 mcg\/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use.<\/span><\/p>\n

0154A – <\/b>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative-free, 10 mcg\/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose<\/span><\/p>\n

Pfizer-BioNTech\u2019s bivalent booster in individuals 12 years or older codes and descriptions:<\/b><\/h3>\n

91312 – <\/b>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative-free, 30 mcg\/0.3 mL dosage, tris-sucrose formulation, for intramuscular use.<\/span><\/p>\n

0124A – <\/b>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative-free, 30 mcg\/0.3 mL dosage, tris-sucrose formulation, booster dose.<\/span><\/p>\n

BillingParadise has already assisted many medical groups and practices to bill<\/a> for the covid-19 screening, vaccination administration, etc, and has helped them receive reimbursement. Billing for covid-19 cases and inpatient stay is complicated. It is wise for healthcare facilities and medical practices to consult experts<\/a> that have already done and succeeded in this billing and then proceed.\u00a0For practices that require enrolment in the provider relief fund, BillingParadise can definitely assist. Schedule a free consultation now!<\/a><\/strong><\/p>\n<\/div><\/div><\/div><\/div><\/section>\n","protected":false},"excerpt":{"rendered":"New CPT codes for COVID-19 Booster Vaccine COVID-19 and its adaptation are still a threat to many individuals in the United States. The CDC has prioritized that people with symptoms even after receiving the covid vaccines that work in public domains, healthcare, and other high-population settings must use these covid booster vaccines for safety measures [...]","protected":false},"author":2,"featured_media":441224,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[745],"tags":[],"class_list":["post-441223","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-coding"],"_links":{"self":[{"href":"https:\/\/www.billingparadise.com\/blog\/wp-json\/wp\/v2\/posts\/441223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.billingparadise.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.billingparadise.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.billingparadise.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.billingparadise.com\/blog\/wp-json\/wp\/v2\/comments?post=441223"}],"version-history":[{"count":7,"href":"https:\/\/www.billingparadise.com\/blog\/wp-json\/wp\/v2\/posts\/441223\/revisions"}],"predecessor-version":[{"id":450231,"href":"https:\/\/www.billingparadise.com\/blog\/wp-json\/wp\/v2\/posts\/441223\/revisions\/450231"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.billingparadise.com\/blog\/wp-json\/wp\/v2\/media\/441224"}],"wp:attachment":[{"href":"https:\/\/www.billingparadise.com\/blog\/wp-json\/wp\/v2\/media?parent=441223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.billingparadise.com\/blog\/wp-json\/wp\/v2\/categories?post=441223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.billingparadise.com\/blog\/wp-json\/wp\/v2\/tags?post=441223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}